Li He

Li He

Auto-generated profile, based on publicly available information

Li He

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, P.R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
RQRundong Qin
Rundong Qin
LHLi He
Li He
ZYZhaowei Yang
Zhaowei Yang
NJNan Jia
Nan Jia
RCRuchong Chen
Ruchong Chen
JLJing Li
Jing Li

27 April 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
LHLi He
Li He
FLFangmei Lin
Fangmei Lin
YZYawen Zhou
Yawen Zhou
MDMeihua Dong
Meihua Dong
MDMingfang Deng
Mingfang Deng
NJNan Jia
Nan Jia
Objective: Emerging evidence has indicated the potential role of DNA damage response in asthma pathogenesis, but the underlying mechanisms remain elusive. Therefore, this study aimed to identify key diagnostic DNA damage response–related genes in asthma and explore their regulatory networks. Methods: Differentially expressed genes between healthy individuals and patients with asthma were identified using the Gene Expression Omnibus database. Hub DNA damage response–related differentially expressed genes were determined via protein–protein interaction network and verified through gene expression analysis. Receiver operating characteristic curve was employed to identify diagnostic genes. Transcription factor–microRNA–target gene interactions were analyzed to uncover the regulatory networks in asthma pathogenesis. In this observational study, reverse transcription quantitative polymerase chain reaction was used to validate gene expression levels in healthy individuals and patients with asthma. Results: Six of the nine hub genes ( ATM , PCNA , CUL4A , PARP2 , HLTF , and NBN ) were identified as key diagnostic genes. These genes may contribute to asthma progression by regulating inflammatory pathways, such as cyclic GMP–AMP synthase–stimulator of interferon genes, senescence-associated secretory phenotype, autophagy, and apoptosis. Three microRNAs and eleven transcription factors were recognized as potential regulators. Reverse transcription quantitative polymerase chain reaction confirmed the downregulation of DNA damage response genes in asthma and revealed distinct expression patterns across different asthma endotypes. Conclusion: Six DNA damage response–related genes may serve as diagnostic biomarkers for asthma, and the transcription factor–microRNA–DNA damage response gene network highlights the role of DNA damage response in asthmatic inflammation.

9 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
LHLi He
Li He
RQRundong Qin
Rundong Qin
ZYZhaowei Yang
Zhaowei Yang
NJNan Jia
Nan Jia
RCRuchong Chen
Ruchong Chen
JLJing Li
Jing Li
BackgroundLaboratory abnormalities associated with disease severity and mortality in patients with coronavirus disease 2019 (COVID-19) have been reported in many observational studies. However, there are significant heterogeneities in patient characteristics and research methodologies in these studies.ObjectivesWe aimed to provide an updated synthesis of the association between laboratory abnormalities and COVID-19 prognosis.MethodsWe conducted an electronic search of PubMed, Scopus, Ovid, Willey, Web of Science, and the China National Knowledge Infrastructure (CNKI) for studies reporting hematological, coagulation, inflammatory, and immunological results during hospital admission of COVID-19 patients with different severities and outcomes.ResultsA total of 64 studies were included in the current meta-analysis, with 8 hematological, 3 coagulation, 5 inflammatory, and 23 immunological variables reported. Of them, white blood cell (WBC) and neutrophil counts (Neu), D-dimer level, procalcitonin (PCT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferretin, serum amyloid A (SAA), interleukins (ILs)–2R, IL-6, and IL-10 were significantly increased in severely ill patients and non-survivors. Meanwhile, non-severely ill patients and survivors presented significantly higher counts of eosinophils, lymphocytes, and CD4+ and CD8+ T cells. A majority of included variables presented with significant heterogeneity, some of which resulted from differing disease severities and ages of included patients.ConclusionsThe current meta-analysis provides a comprehensive and updated synthesis of the association between admission laboratory abnormalities with severity and mortality of COVID-19. Our results highlight that increases in the levels of PCT, ESR, CRP, ferretin, SAA, IL-2R, IL-6, and IL-10 were associated with disease deterioration, whereas elevated eosinophils, lymphocytes, and T-cell subsets might serve as indicators of favorable outcomes.